Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 6/20 | 0.61 |
| ▸ | PADI2 | Q9Y2J8 | 4/20 | 0.61 |
| ▸ | PADI6 | Q6TGC4 | 3/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026327 | 0.87 | PADI4 (0.72) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL10060225 | 0.80 | PADI4 (0.67) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL10061251 | 0.78 | PDE4A (0.57) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL16541247 | 0.78 | PDE4A (0.48) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL2701630 | 0.78 | PADI4 (0.73) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL28476721 | 0.77 | PADI4 (0.72) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL10060238 | 0.76 | PADI6 (0.55) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL29453253 | 0.76 | PADI4 (1.00) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL16124246 | 0.74 | PADI4 (0.72) | PADI4PADI2PADI6PDE4APDE4B | |
| SCHEMBL10026321 | 0.74 | PDE4A (0.67) | PADI4PADI2PADI6PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969333-B2 | Therapeutic compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | PADI4 1/4885PADI2 2/4885PADI6 5/4885 |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | PADI4 1/4885PADI2 2/4885PADI6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.